In a phase 2 study, the use of a DC vaccine electroporated with Wilms’ tumor 1 (WT1) mRNA in patients with acute myeloid leukemia was shown to be a safe and feasible regimen in promoting tumor infiltration of multi-epitope WT1-specific CD8+ T cells and effectively prevent or delay cancer recurrence after standard chemotherapy [270]. This evidence concerns the gene WT1 and acute myeloid leukemia.